BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11223836)

  • 1. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
    Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
    J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
    Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
    Pestieau SR; Stuart OA; Sugarbaker PH
    Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intraperitoneal gemcitabine in a rat model.
    Pestieau SR; Stuart OA; Chang D; Jacquet P; Sugarbaker PH
    Tumori; 1998; 84(6):706-11. PubMed ID: 10080682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats.
    Mas-Fuster MI; Ramon-Lopez A; Lacueva J; Compañ A; Más-Serrano P; Nalda-Molina R
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):621-627. PubMed ID: 28168311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
    Elias D; Bonnay M; Puizillou JM; Antoun S; Demirdjian S; El OA; Pignon JP; Drouard-Troalen L; Ouellet JF; Ducreux M
    Ann Oncol; 2002 Feb; 13(2):267-72. PubMed ID: 11886004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
    Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of heated intraperitoneal oxaliplatin.
    Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.
    Leinwand JC; Bates GE; Allendorf JD; Chabot JA; Lewin SN; Taub RN
    Ann Surg Oncol; 2013 Apr; 20(4):1101-4. PubMed ID: 23456384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
    Los G; Mutsaers PH; Ruevekamp M; McVie JG
    Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of oxaliplatin after intraperitoneal administration with hyperthermia in Wistar rats.
    Mas-Fuster MI; Ramon-Lopez A; Lacueva FJ; Arroyo A; Más-Serrano P; Nalda-Molina R
    Eur J Pharm Sci; 2018 Jul; 119():22-30. PubMed ID: 29626594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.
    Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D
    Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.
    Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model.
    Piché N; Leblond FA; Sidéris L; Pichette V; Drolet P; Fortier LP; Mitchell A; Dubé P
    Ann Surg; 2011 Jul; 254(1):138-44. PubMed ID: 21494122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers.
    Stewart JH; Shen P; Russell G; Fenstermaker J; McWilliams L; Coldrun FM; Levine KE; Jones BT; Levine EA
    Ann Surg Oncol; 2008 Aug; 15(8):2137-45. PubMed ID: 18493824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.
    Jacquet P; Averbach A; Stuart OA; Chang D; Sugarbaker PH
    Cancer Chemother Pharmacol; 1998; 41(2):147-54. PubMed ID: 9443628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
    Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques.
    Ortega-Deballon P; Facy O; Jambet S; Magnin G; Cotte E; Beltramo JL; Chauffert B; Rat P
    Ann Surg Oncol; 2010 Jul; 17(7):1957-63. PubMed ID: 20143265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC).
    Verhulst J
    Int J Hyperthermia; 2013; 29(1):62-70. PubMed ID: 23311379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin for chemotherapeutic treatment and prevention of experimental peritoneal carcinomatosis in rats comparing the intraperitoneal and intravenous application mode.
    Hribaschek A; Meyer F; Ridwelski K; Kuester D; Lippert H
    Eur Surg Res; 2010; 44(2):74-81. PubMed ID: 20051689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.